Target Name: GOLT1B
NCBI ID: G51026
Review Report on GOLT1B Target / Biomarker Content of Review Report on GOLT1B Target / Biomarker
GOLT1B
Other Name(s): Putative NF-kappa-B-activating protein 470 | putative NF-kappa-B-activating protein 470 | hGOT1a | germ cell tumor 2 | YMR292W | CGI-141 | Vesicle transport protein GOT1B | Germ cell tumor 2 | GOT1 | GOT1B | Golgi transport 1 homolog B | golgi transport 1B | GCT2 | GOT1B_HUMAN | GOT1A | Golgi transport 1B

GOLT1B: A Potential Drug Target and Biomarker for NF-kappa-B Activation

The nuclear factor kappa B (NF-kappa-B) is a protein that plays a crucial role in regulating various cellular processes, including inflammation, cell survival, and angiogenesis. GOLT1B, also known as Putative NF-kappa-B-Activating Protein 470, is a protein that has been identified as a potential drug target and biomarker for NF-kappa-B activation.

GOLT1B is a 24.5 kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is a member of the kappa B subfamily of the NF-kappa-B signaling pathway, which includes several pro-inflammatory cytokines that play a central role in the regulation of cellular processes such as inflammation, cell survival, and angiogenesis.

GOLT1B Functions as an NF-kappa-B Activating Protein

GOLT1B is a potent NF-kappa-B activator, which means that it can induce the activity of the NF-kappa-B signaling pathway. This is done through its ability to interact with and activate several subunits of the NF-kappa-B complex. GOLT1B can interact with and activate the p65 subunit of the NF-kappa-B kinase, which is a critical subunit for the NF-kappa-B signaling pathway.

The p65 subunit of the NF-kappa-B kinase is a 29 kDa protein that is composed of two subunits, p65伪 and p65尾. GOLT1B can interact with the N-terminus of p65伪 and the C-terminus of p65尾, which allows it to activate the NF-kappa-B signaling pathway.

GOLT1B has been shown to play a role in the regulation of various cellular processes, including inflammation, cell survival, and angiogenesis. For example, GOLT1B has been shown to be involved in the regulation of inflammation, as it has been shown to induce the production of pro-inflammatory cytokines such as TNF-伪 and IL-1尾.

GOLT1B has also been shown to play a role in the regulation of cell survival, as it has been shown to promote the survival of certain cancer cell lines. This is done through its ability to interact with and activate several anti-apoptotic proteins, including Bcl-2.

GOLT1B has also been shown to play a role in the regulation of angiogenesis, as it has been shown to promote the formation of new blood vessels in wound healing.

Drug Targeting and Biomarker

GOLT1B is a potential drug target, as its activity as an NF-kappa-B activating protein makes it a promising target for small molecules that can inhibit its activity. Several studies have shown that inhibitors of GOLT1B can inhibit the activity of the NF-kappa-B signaling pathway, including the production of pro-inflammatory cytokines and the promotion of cell survival.

GOLT1B has also been identified as a potential biomarker for the evaluation of therapeutic approaches for various diseases, including cancer, inflammation, and cardiovascular disease. This is done through its expression and levels in various tissues, including blood, urine, and tissue samples.

Conclusion

GOLT1B is a protein that has been identified as a potential drug target and biomarker for NF-kappa-B activation. Its activity as an NF-kappa-B activating protein makes it a promising target for small molecules that can inhibit its activity. Further studies are needed to determine the full scope of GOLT1B's

Protein Name: Golgi Transport 1B

Functions: May be involved in fusion of ER-derived transport vesicles with the Golgi complex

The "GOLT1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLT1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GON4L | GON7 | GOPC | GORAB | GORASP1 | GORASP2 | GOSR1 | GOSR2 | GOT1 | GOT1-DT | GOT1L1 | GOT2 | GOT2P1 | GP1BA | GP1BB | GP2 | GP5 | GP6 | GP9 | GPA33 | GPAA1 | GPALPP1 | GPAM | GPANK1 | GPAT2 | GPAT3 | GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17